Cargando…
Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis
PURPOSE: Recurrences and deaths are known to occur, even if less frequently, in small, node-negative breast cancer patients, and decision on adjuvant treatments remains controversial. In the present analysis, we evaluate recurrence risk in patients with pT1 a, b, c, node-negative, breast cancer, acc...
Autores principales: | Gamucci, T., Vaccaro, A., Ciancola, F., Pizzuti, L., Sperduti, I., Moscetti, L., Longo, F., Fabbri, M. A., Giampaolo, M. A., Mentuccia, L., Di Lauro, L., Vici, P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3625404/ https://www.ncbi.nlm.nih.gov/pubmed/23411686 http://dx.doi.org/10.1007/s00432-013-1388-2 |
Ejemplares similares
-
Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients
por: Gamucci, T., et al.
Publicado: (2013) -
Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study
por: Gamucci, Teresa, et al.
Publicado: (2014) -
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting
por: Pizzuti, Laura, et al.
Publicado: (2017) -
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial
por: Moscetti, Luca, et al.
Publicado: (2017) -
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study
por: Vici, Patrizia, et al.
Publicado: (2014)